Imugene Reports New Complete and Partial Responses in CAR T Trial [VIDEO]

Imugene's azer-cel Phase 1b trial has delivered a fresh complete response in CAR T-naïve Cohort 2 and a partial response conversion in the BTKi cohort, lifting response rates to 81% and 86%.

By Josua Ferreira -

Key Takeaways

  • Imugene's CAR T-naïve Cohort 2 now stands at 22 responders from 27 patients, an 81% ORR, after a new marginal zone lymphoma complete response at Day 28.
  • The BTKi combination Cohort 3 reached an 86% ORR (six of seven patients) after a Richter's Transformation patient converted from stable disease to partial response.
  • Cohort 3 is only seven patients, so a single conversion moved its ORR from 71% to 86%, and the figure should be read with that in mind.
  • Azer-cel is an off-the-shelf CD19-targeting CAR T, with enrolment continuing across ten US and five Australian sites.
  • Further updates are promised as data matures, but Imugene gave no dates, so there is no scheduled catalyst.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher